This study also identified IL-6 and IL-10 as markers of TLR4 activation in HCC and subjects with NAFLD and obesity as the target population who would benefit from TLR4 inhibition treatment for HCC chemoprevention. Here, IL10 is linked to metabolic dysfunction-associated steatotic liver disease.